Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii
| Autor: | Peter B. Madrid, Amit K. Galande, Maria Torres-Ortiz, Sidharth Chopra, Leslie A. Hokama, Kristien Mortelmans, Krishna Kodukula, Mary J. Tanga |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Acinetobacter baumannii
Microbiology (medical) Drug medicine.drug_class media_common.quotation_subject Antibiotics Microbial Sensitivity Tests Drug resistance Biology Pharmacology Microbiology Drug Resistance Multiple Bacterial Drug Discovery medicine Humans Pharmacology (medical) Drug Approval Repurposing media_common Antibacterial agent Cross Infection United States Food and Drug Administration Tyrothricin Antimicrobial biology.organism_classification United States Anti-Bacterial Agents Infectious Diseases Drug development Acinetobacter Infections |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 65:2598-2601 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dkq353 |
| Popis: | Objective: The rising occurrence of drug-resistant pathogens accentuates the need to identify novel antibiotics. We wanted to identify new scaffolds for drug discovery by repurposing FDA-approved drugs against Acinetobacter baumannii, an emerging Gram-negative nosocomial drug-resistant pathogen. Materials and methods: In this study, we screened 1040 FDA-approved drugs against drug-susceptible A. baumannii ATCC 17978 and drug-resistant A. baumannii BAA-1605. Results and discussion: Twenty compounds exhibited significant antimicrobial activity (MIC ≤8 mg/L) against ATCC 17978 while only five compounds showed such activity against BAA-1605. Among the most notable results, tyrothricin, a bactericidal antibiotic typically active only against Gram-positive bacteria, exhibited equipotent activity against both strains. Conclusion: The paucity of identified compounds active against drug-resistant A. baumannii exemplifies its ability to resist antimicrobials as well as the resilience of drug-resistant Gram-negative pathogens. Repurposing of approved drugs is a viable alternative to de novo drug discovery and development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|